{"id":"https://openalex.org/W4286293836","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.5074","title":"Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.","display_name":"Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis.","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4286293836","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.5074"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.5074","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.5074","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.5074","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5075093609","display_name":"Arun Azad","orcid":"https://orcid.org/0000-0001-7350-5622","observed_orcids":["https://orcid.org/0000-0001-7350-5622"]},"institutions":[{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Arun Azad","raw_affiliation_strings":["Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;","institution_ids":["https://openalex.org/I2800555584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001736199","display_name":"Taro Iguchi","orcid":"https://orcid.org/0000-0002-7067-6642","observed_orcids":["https://orcid.org/0000-0002-7067-6642"]},"institutions":[{"id":"https://openalex.org/I16568816","display_name":"Kanazawa Medical University","ror":"https://ror.org/0535cbe18","country_code":"JP","type":"education","lineage":["https://openalex.org/I16568816"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Taro Iguchi","raw_affiliation_strings":["Kanazawa Medical University, Ishikawa, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kanazawa Medical University, Ishikawa, Japan;","institution_ids":["https://openalex.org/I16568816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019977496","display_name":"B. Y\u0430. Alekseev","orcid":"https://orcid.org/0000-0002-3398-4128","observed_orcids":["https://orcid.org/0000-0002-3398-4128"]},"institutions":[{"id":"https://openalex.org/I4210139937","display_name":"P.A. Hertzen Moscow Oncology Research Institute","ror":"https://ror.org/04rbazs75","country_code":"RU","type":"facility","lineage":["https://openalex.org/I4210117042","https://openalex.org/I4210139937"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"Boris Alekseev","raw_affiliation_strings":["Hertzen Moscow Cancer Research Institute, Moscow, Russian Federation;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hertzen Moscow Cancer Research Institute, Moscow, Russian Federation;","institution_ids":["https://openalex.org/I4210139937"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088518998","display_name":"Neal D. Shore","orcid":"https://orcid.org/0000-0001-5767-0548","observed_orcids":["https://orcid.org/0000-0001-5767-0548"]},"institutions":[{"id":"https://openalex.org/I4210165013","display_name":"Carolina Urologic Research Center","ror":"https://ror.org/05vk9vy20","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210165013"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neal D. Shore","raw_affiliation_strings":["Carolina Urologic Research Center, Myrtle Beach, SC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Carolina Urologic Research Center, Myrtle Beach, SC;","institution_ids":["https://openalex.org/I4210165013"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013087961","display_name":"Jennifer E. Sugg","orcid":"https://orcid.org/0000-0003-2208-077X","observed_orcids":["https://orcid.org/0000-0003-2208-077X"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Sugg","raw_affiliation_strings":["Astellas Pharma Inc., Northbrook, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Inc., Northbrook, IL;","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109651628","display_name":"Gabriel P. Haas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel P. Haas","raw_affiliation_strings":["Astellas Pharma Inc., Northbrook, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Inc., Northbrook, IL;","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081784168","display_name":"Michele Wozniak","orcid":"https://orcid.org/0009-0000-1705-6105","observed_orcids":["https://orcid.org/0009-0000-1705-6105"]},"institutions":[{"id":"https://openalex.org/I4210165171","display_name":"Astellas Pharma (United States)","ror":"https://ror.org/05pw69n24","country_code":"US","type":"company","lineage":["https://openalex.org/I142395110","https://openalex.org/I4210165171"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michele Wozniak","raw_affiliation_strings":["Astellas Pharma Inc., Northbrook, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Astellas Pharma Inc., Northbrook, IL;","institution_ids":["https://openalex.org/I4210165171"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073771007","display_name":"Thomas O\u2019Brien","orcid":"https://orcid.org/0000-0002-9161-8070","observed_orcids":["https://orcid.org/0000-0002-9161-8070"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas O'Brien","raw_affiliation_strings":["Pfizer Inc., La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., La Jolla, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048557438","display_name":"Douglas Laird","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Laird","raw_affiliation_strings":["Pfizer Inc., La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., La Jolla, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086583298","display_name":"Arnulf Stenzl","orcid":"https://orcid.org/0000-0003-4207-9928","observed_orcids":["https://orcid.org/0000-0003-4207-9928"]},"institutions":[{"id":"https://openalex.org/I8087733","display_name":"University of T\u00fcbingen","ror":"https://ror.org/03a1kwz48","country_code":"DE","type":"education","lineage":["https://openalex.org/I8087733"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Arnulf Stenzl","raw_affiliation_strings":["University Hospital, Eberhard Karls University of T\u00fcbingen, T\u00fcbingen, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital, Eberhard Karls University of T\u00fcbingen, T\u00fcbingen, Germany;","institution_ids":["https://openalex.org/I8087733"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038489185","display_name":"Andrew J. Armstrong","orcid":"https://orcid.org/0000-0001-7012-1754","observed_orcids":["https://orcid.org/0000-0001-7012-1754"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew J. Armstrong","raw_affiliation_strings":["Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC;","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4390039326"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"5074","last_page":"5074"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.753000020980835},{"id":"https://openalex.org/keywords/metastatic-hormone-sensitive-prostate-cancer","display_name":"metastatic hormone-sensitive prostate cancer","score":0.953000009059906},{"id":"https://openalex.org/keywords/enzalutamide","display_name":"enzalutamide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/androgen-deprivation-therapy","display_name":"androgen deprivation therapy","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pharmacogenomics","display_name":"pharmacogenomics","score":0.7590000033378601},{"id":"https://openalex.org/keywords/tumor-volume","display_name":"tumor volume","score":0.34299999475479126},{"id":"https://openalex.org/keywords/metastatic-stage","display_name":"metastatic stage","score":0.3709999918937683},{"id":"https://openalex.org/keywords/baseline-characteristics","display_name":"baseline characteristics","score":0.3659999966621399},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.628000020980835},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.546999990940094},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.5059999823570251},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.5230000019073486},{"id":"https://openalex.org/keywords/parp-inhibitor-resistance","display_name":"PARP inhibitor resistance","score":0.5149999856948853},{"id":"https://openalex.org/keywords/brca1","display_name":"BRCA1","score":0.3319999873638153},{"id":"https://openalex.org/keywords/brca2","display_name":"BRCA2","score":0.9229999780654907},{"id":"https://openalex.org/keywords/atm","display_name":"ATM","score":0.6470000147819519},{"id":"https://openalex.org/keywords/attenuated-total-reflectance","display_name":"ATR","score":0.3889999985694885}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8534480333328247},{"id":"https://openalex.org/C2776551883","wikidata":"https://www.wikidata.org/wiki/Q1996756","display_name":"Enzalutamide","level":5,"score":0.6229074597358704},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.552286684513092},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5463427305221558},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.5463349223136902},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.47017067670822144},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.45050692558288574},{"id":"https://openalex.org/C67761136","wikidata":"https://www.wikidata.org/wiki/Q2105849","display_name":"Post-hoc analysis","level":2,"score":0.4172828495502472},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.06601491570472717}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.5074","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.5074","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.5074","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7162574120","https://openalex.org/W3135210268","https://openalex.org/W2946985555","https://openalex.org/W2921268519","https://openalex.org/W4281703968","https://openalex.org/W2978582613","https://openalex.org/W3088127785","https://openalex.org/W4324136974","https://openalex.org/W4212967167","https://openalex.org/W4297821480"],"abstract_inverted_index":{"5074":[0],"Background:":[1],"DDR":[2,53,84,125,270,317],"alterations":[3,54,271],"are":[4],"associated":[5,56],"with":[6,16,22,25,61,67,181,213,274,279,286],"poorer":[7],"prognosis,":[8],"including":[9],"shorter":[10],"overall":[11],"survival":[12],"(OS),":[13],"in":[14,59,63,89,101,110,191,228,272,276,284,311],"patients":[15,21,60,105,152,164,232,273,285],"mHSPC.":[17],"In":[18],"ARCHES":[19,157],"(NCT02677896),":[20],"mHSPC":[23,62,68,275],"treated":[24],"ENZA":[26,74],"+":[27,43,77,81,141,145],"ADT":[28,78],"had":[29,177,205],"a":[30,111,266],"reduced":[31],"risk":[32],"of":[33,52,104,118,150,162,184,269],"radiographic":[34],"progression":[35],"or":[36,79],"death":[37],"and":[38,55,121,195,233,252],"improved":[39],"OS":[40],"versus":[41],"PBO":[42,80,144],"ADT.":[44,82],"This":[45,261],"post":[46,262],"hoc":[47,263],"analysis":[48,139,264],"assessed":[49],"the":[50,102,156,257,280],"prevalence":[51,161,268],"baseline":[57,119,312],"characteristics":[58,123,149,314],"ARCHES.":[64],"Methods:":[65],"Patients":[66],"(n=1150)":[69],"were":[70,99,127,136,153,243,248],"randomized":[71],"1:1":[72],"to":[73,108,155],"(160":[75],"mg/day)":[76],"Germline":[83],"alteration":[85],"testing":[86],"was":[87,165,189,226,255],"performed":[88],"blood":[90],"using":[91],"Ambry":[92],"Genetics":[93],"CustomNext-Cancer":[94],"panel;":[95],"16":[96],"DDR-related":[97],"genes":[98],"reported":[100,283],"subset":[103],"who":[106],"consented":[107],"participate":[109],"pharmacogenomic":[112],"study":[113],"(n=664;":[114],"Table).":[115,171],"Descriptive":[116],"analyses":[117],"demographics":[120],"disease":[122,188,207,221,313],"by":[124],"status":[126],"performed.":[128],"Results:":[129],"Of":[130,172,200,238],"664":[131],"patient":[132],"samples":[133],"tested,":[134],"652":[135],"evaluable":[137],"for":[138],"(ENZA":[140],"ADT,":[142,146],"n=326;":[143],"n=326).":[147],"Baseline":[148],"these":[151],"similar":[154],"intent-to-treat":[158],"population.":[159],"The":[160],"DDR+":[163,173,194,201,231,239],"lower":[166,267],"than":[167],"expected":[168],"(n=34/652,":[169],"5.2%;":[170],"patients,":[174,202,240],"13":[175],"(38.2%)":[176],"low-volume":[178],"disease,":[179],"compared":[180,212,278],"228":[182],"(36.9%)":[183],"DDR\u2212":[185,198,216,236],"patients.":[186,199,217,237],"High-volume":[187],"present":[190,227],"21":[192],"(61.8%)":[193],"390":[196],"(63.1%)":[197],"6":[203],"(17.6%)":[204],"localized":[206],"at":[208,222],"initial":[209,223],"diagnosis":[210,224],"(M0),":[211],"145":[214],"(23.5%)":[215],"De":[218],"novo":[219],"metastatic":[220,287],"(M1)":[225],"28":[229],"(82.4%)":[230],"465":[234],"(75.2%)":[235],"29":[241],"(85.3%)":[242],"from":[244,249,256],"Europe,":[245],"four":[246],"(11.8%)":[247],"North":[250],"America,":[251],"one":[253],"(2.9%)":[254],"Asia-Pacific":[258],"region.":[259],"Conclusions:":[260],"found":[265],"ARCHES,":[277],"7\u201312%":[281],"previously":[282],"castration-resistant":[288],"prostate":[289],"cancer":[290],"(Lozano":[291],"et":[292,299],"al.":[293,300],"Br":[294],"J":[295,303],"Cancer":[296],"2021;":[297],"Pritchard":[298],"N":[301],"Engl":[302],"Med":[304],"2016).":[305],"We":[306],"did":[307],"not":[308],"identify":[309],"differences":[310],"based":[315],"on":[316],"status.":[318],"Clinical":[319],"trial":[320],"information:":[321],"NCT02677896.":[322],"[Table:":[323],"see":[324],"text]":[325]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-07-21T00:00:00"}